[CROATIAN SOCIETY FOR MEDICAL ONCOLOGY CLINICAL GUIDELINES FOR DIAGNOSIS, TREATMENT AND FOLLOW-UP OF PATIENTS WITH MELANOMA].
Melanoma in the Western world has an increasing incidence. One of the most important factor for the increase in incidence is sporadic, uncontrolled exposure to the sun. The basis for the treatment of primary melanoma is surgical treatment. Treatment of metastatic disease of melanoma in recent years experienced significant changes. BRAF and MEK inhibitors, immunotherapy with programmed cell-death immune checkpoint inhibitors (anti-PD-1-antibodies) are new options for the treatment of metastatic disease. A mulitidisiplinary team of Croatian Society for Medical Oncology provides recommendations for diagnosis, treatment and follow-up of melanoma primarily driven to the discovery of new drugs and therapeutic options, that change the prognosis of patients with metastatic melanoma.
Davorin
D
Herceg
Daska Stulhofer
DS
Buzina
Romana
R
Ceović
Snjezana
S
Dotlić
Ivana
I
Ilić
Sanda Smuđ
SS
Orehovec
Gordana Horvatić
GH
Herceg
Davor
D
Mijatović
Robert
R
Separović
Tajana
T
Silovski
Damir
D
Vrbanec
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017523:Croatia; D019468:Disease Management; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008545:Melanoma / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D009362:Neoplasm Metastasis; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D013514:Surgical Procedures, Operative / Q000379:methods*
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D048493:Proto-Oncogene Proteins B-raf